TAKEDA PHARMACEUTICAL CO LTD
TAKThe Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect".
Drugs in Pipeline
201
Phase 3 Programs
136
Upcoming Catalysts
11
Next Catalyst
This month
Market Overview
Stock performance and key metrics
11 upcoming, 1 past
Upcoming FDA decisions
Chlorthalidone
Hypertension
Adynovate
Hemophilia A
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
HYQVIA
Primary Immunodeficiency Diseases (PID)
Active Comparator
Psoriatic Arthritis
Bismuth-Containing Quadruple Therapy
Duodenal Ulcer
Azilsartan Medoxomil and amlodipine
Hypertension
Alogliptin and voglibose
Type 2 Diabetes Mellitus
Dexlansoprazole MR QD
Gastroesophageal Reflux
Soticlestat
Dravet Syndrome (DS)
Deucravacitinib
Plaque Psoriasis
Epoetin
Chronic Kidney Disease
von Willebrand factor (Recombinant)
Von Willebrand Disease
Lansoprazole
Esophagitis, Reflux
Vedolizumab IV
Moderately to Severely Active Ulcerative Colitis
Azilsartan medoxomil and olmesartan
Hypertension
IGSC 20% infusion
Primary Immunodeficiency Disease
Lu AA21004
Major Depressive Disorder
TAK-536TCH tablet
Essential Hypertension
YF-17D
Dengue
Ixazomib Citrate
Multiple Myeloma
Glipizide
Diabetes Mellitus
Vortioxetine
Major Depressive Disorder
Lapaquistat acetate and simvastatin
Hypercholesterolemia
Upadacitinib
Crohn's Disease
MOVIPREP
Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
Velaglucerase Alfa
Gaucher Disease
Lapaquistat acetate and rosuvastatin
Hypercholesterolemia
Rosiglitazone
Diabetes Mellitus
NE-58095 IR
Involutional Osteoporosis
TAK-881
Primary Immunodeficiency Diseases (PID)
Relugolix
Uterine Fibroids
Teduglutide
Short Bowel Syndrome
TAK-279
Plaque Psoriasis
TVP-1012
Parkinson's Disease
Actovegin
Peripheral Arterial Diseases
9vHPV Vaccine
Dengue Fever
TachoSil®
Hemorrhage
Vonoprazan
Gastroesophageal Reflux
REPLAGAL
Fabry Disease
Zopiclone
Balance
TAK-536
Hypertension
Elritercept
Myelodysplastic Syndromes
Dexlansoprazole
Gastroesophageal Reflux Disease
Febuxostat
Gout
Ramipril
Hypertension
Apremilast
Plaque Psoriasis
TAK-330
Coagulation Disorder
Voglibose
Type 2 Diabetes Mellitus
TAK-771
Primary Immunodeficiency Diseases (PID)
Surgicel® Original
Bleeding
TAP-144-SR(6M)
Prostate Cancer
Valsartan
Hypertension
Fasiglifam
Diabetes Mellitus, Type 2
Alogliptin Benzoate
Diabetes Mellitus, Type 2
Febuxostat IR
Gout
TAK-360
Idiopathic Hypersomnia
TVP-1012 1mg
Parkinson's Disease
TAK-672
Acquired Hemophilia A
Vedolizumab SC
Ulcerative Colitis
Lubiprostone
Constipation
Metformin HCl
Diabetes Mellitus
TAK-667
Hereditary Angioedema
Leuprorelin SR
Prostatic Neoplasms, Locally Advanced
VONVENDI
Von Willebrand Disease (VWD)
Gefarnate
Stomach Ulcer
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Intranasal Fentanyl Spray (INFS)
Break Through Pain
TVP-1012 0.5mg
Parkinson's Disease
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Dengue Fever
Metformin hydrochloride
Type 2 Diabetes Mellitus
Azilsartan
Hypertension
Lansoprazole microgranules suspension
Gastroesophageal Reflux Disease
Peginesatide
Anemia
Concomitant Antibiotic Therapy
Pouchitis
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Hypertension
TAK-743 300 mg
Hereditary Angioedema
Alogliptin and metformin
Type 2 Diabetes Mellitus
Cyclobenzaprine HCl
Neck Pain
TAK-625
Alagille Syndrome (ALGS)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
TAK-875
Diabetes Mellitus
Parathyroid Hormone (PTH)
Osteoporosis
TAK-003
Dengue Fever
TAK-816
Healthy Volunteers
Brigatinib
ALK-positive Advanced NSCLC
Lapaquistat Acetate
Dyslipidemia
Cyproterone acetate
Adenocarcinoma, Prostate
Escitalopram
Treatment Outcome
Maribavir
Cytomegalovirus (CMV)
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
TAK-816+ DPT-TAKEDA
Immunization
Lapaquistat acetate and lipid-lowering therapy
Type 2 Diabetes
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Lapaquistat acetate and atorvastatin
Hypercholesterolemia
Alectinib
ALK+ Advanced NSCLC
HAV Vaccine
Healthy Volunteers
Ramelteon
Sleep Initiation and Maintenance Disorders
TDV
Dengue Fever
Dexlansoprazole MR
Gastroesophageal Reflux Disease
Ixazomib
Multiple Myeloma
SYR-472
Diabetes Mellitus
TAK-583
Neuralgia, Postherpetic
Darvadstrocel
Crohn's Disease
Omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-536CCB
Grade I or II Essential Hypertension
Lansoprazole and naproxen and aspirin
Osteoarthritis
Glyburide
Diabetes Mellitus
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Cancer
Lapaquistat acetate and additional lipid-lowering therapy
Hypercholesterolemia
Vedolizumab
Colitis, Ulcerative
Pioglitazone and Metformin
Diabetes Mellitus
Idursulfase-IT
Hunter Syndrome
Lanadelumab
Angioedema
Rapid-acting insulin secretagogue
Diabetes Mellitus
TAK-861
Narcolepsy Type 1
Candesartan
Heart Failure
Venticute
Pneumonia
Vortioxetine tablets
Major Depressive Disorder
Alogliptin
Diabetes Mellitus, Type 2
Azilsartan medoxomil - chlorthalidone
Essential Hypertension
Leuprorelin
Prostatic Neoplasms
Resatorvid
Sepsis
Vedolizumab 300 mg IV
Colitis, Ulcerative
Vedolizumab SC 108 mg
Crohn's Disease
Azilsartan medoxomil
Essential Hypertension
Alogliptin and glyburide
Diabetes Mellitus
Zasocitinib
Psoriatic Arthritis
SYR-322-MET
Clinical Pharmacology
TAK-438 10 mg
Non-erosive Gastroesophageal Reflux Disease
Vonicog Alfa
Von Willebrand Disease (VWD)
TAK-019
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
TAK-438
Gastric Ulcers
Azilsartan medoxomil and chlorthalidone
Essential Hypertension
TAK-559
Diabetes Mellitus
TAK-411
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
Dengue Fever
Leuprorelin acetate
Endometriosis
Zasocitinib (Dose A)
Hidradenitis Suppurativa
Norwalk VLP vaccine
Acute Gastroenteritis
NoV Vaccine
Healthy Volunteers
TAK-981
Advanced or Metastatic Solid Tumors
TAK-954
Postoperative Gastrointestinal Dysfunction
TAK-079
Primary Immune Thrombocytopenia
TAK-063 20 mg
Schizophrenia
MCC-135
Congestive Heart Failure
Brentuximab Vedotin
Lymphoma
Panitumumab + TAS-102
Colorectal Cancer
Pevonedistat
Acute Myeloid Leukemia (AML)
TAK-071
Parkinson Disease
Leuprorelin (GF)
Uterine Fibroids
Olmesartan
Hypertension
Candesartan cilexetil
Essential Hypertension
Lapaquistat acetate and fenofibrate
Hyperlipidemias
Hepatitis A Vaccine
Healthy Volunteers
NoV GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
TAK-007
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Ponatinib
Myeloid Leukemia, Chronic, Chronic Phase
TAK-853
Ovarian Cancer
TAK-850 0.5 mL injection
Influenza Infection
TIMP-GLIA
Celiac Disease
TAK-662
Congenital Protein C Deficiency
TAK-850
Influenza Infection
GDX012
Leukemia
TAK-188
Advanced or Metastatic Solid Tumors
Levothyroxine sodium new formulation
Hypothyroidism
TD-8954
Enteral Feeding Intolerance
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Dengue Fever
TAK-341
Multiple System Atrophy
Norovirus Bivalent VLP Vaccine
Norovirus Prevention
TAK-442
Acute Coronary Syndrome
vortioxetine (Lu AA21004)
Depressive Disorder, Major
NDI-034858
Psoriatic Arthritis
TAK-062
Celiac Disease
Pioglitazone and insulin
Diabetes Mellitus
Ramelteon and doxepin
Sleep Initiation and Maintenance Disorders
Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
Subcutaneous injection of TAK-850
Influenza Infection
TAK-861 2 mg
Narcolepsy Type 2
TAK-128
Diabetic Neuropathies
TAK-385
Uterine Fibroids
TAK-101
Celiac Disease
Dazostinag
Solid Neoplasms
TAK-919
Coronavirus Disease (COVID-19)
TAK-783 and methotrexate
Arthritis, Rheumatoid
Norovirus Bivalent Vaccine
Prevention From Norovirus Infection
Ilaprazole
Esophagitis
TDV Liquid Formulation 1
Dengue Fever
Pioglitazone and atorvastatin
Cardiovascular Diseases
TAK-272
Type 2 Diabetes Mellitus and Microalbuminuria
GI.1/GII.4 (15/15)
Norovirus
TAK-951
Postoperative Nausea and Vomiting (PONV)
NDI-034858 study drug
Moderate to Severe Plaque Psoriasis
Namilumab
Rheumatoid Arthritis
TAK-788
Carcinoma, Non-Small-Cell Lung
Pioglitazone and ramipril
Inflammation
TAK-935
Developmental and/or Epileptic Encephalopathies
TAK-715 and methotrexate
Arthritis, Rheumatoid
Niraparib
Ovarian Cancer
Pioglitazone and azilsartan
Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Chlorthalidone | Phase 3 | Hypertension | - | - |
Adynovate | Phase 3 | Hemophilia A | - | - |
Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - | - |
HYQVIA | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Active Comparator | Phase 3 | Psoriatic Arthritis | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Duodenal Ulcer | - | - |
Azilsartan Medoxomil and amlodipine | Phase 3 | Hypertension | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR QD | Phase 3 | Gastroesophageal Reflux | - | - |
Soticlestat | Phase 3 | Dravet Syndrome (DS) | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Epoetin | Phase 3 | Chronic Kidney Disease | - | - |
von Willebrand factor (Recombinant) | Phase 3 | Von Willebrand Disease | - | - |
Lansoprazole | Phase 3 | Esophagitis, Reflux | - | - |
Vedolizumab IV | Phase 3 | Moderately to Severely Active Ulcerative Colitis | - | - |
Azilsartan medoxomil and olmesartan | Phase 3 | Hypertension | - | - |
IGSC 20% infusion | Phase 3 | Primary Immunodeficiency Disease | - | - |
Lu AA21004 | Phase 3 | Major Depressive Disorder | - | - |
TAK-536TCH tablet | Phase 3 | Essential Hypertension | - | - |
YF-17D | Phase 3 | Dengue | - | - |
Ixazomib Citrate | Phase 3 | Multiple Myeloma | - | - |
Glipizide | Phase 3 | Diabetes Mellitus | - | - |
Vortioxetine | Phase 3 | Major Depressive Disorder | - | - |
Lapaquistat acetate and simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Upadacitinib | Phase 3 | Crohn's Disease | - | - |
MOVIPREP | Phase 3 | Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel. | - | - |
Velaglucerase Alfa | Phase 3 | Gaucher Disease | - | - |
Lapaquistat acetate and rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
Rosiglitazone | Phase 3 | Diabetes Mellitus | - | - |
NE-58095 IR | Phase 3 | Involutional Osteoporosis | - | - |
TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
TAK-279 | Phase 3 | Plaque Psoriasis | - | - |
TVP-1012 | Phase 3 | Parkinson's Disease | - | - |
Actovegin | Phase 3 | Peripheral Arterial Diseases | - | - |
9vHPV Vaccine | Phase 3 | Dengue Fever | - | - |
TachoSil® | Phase 3 | Hemorrhage | - | - |
Vonoprazan | Phase 3 | Gastroesophageal Reflux | - | - |
REPLAGAL | Phase 3 | Fabry Disease | - | - |
Zopiclone | Phase 3 | Balance | - | - |
TAK-536 | Phase 3 | Hypertension | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Febuxostat | Phase 3 | Gout | - | - |
Ramipril | Phase 3 | Hypertension | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
TAK-330 | Phase 3 | Coagulation Disorder | - | - |
Voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-771 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - | - |
Surgicel® Original | Phase 3 | Bleeding | - | - |
TAP-144-SR(6M) | Phase 3 | Prostate Cancer | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Fasiglifam | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Alogliptin Benzoate | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
TAK-360 | Phase 3 | Idiopathic Hypersomnia | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
TAK-672 | Phase 3 | Acquired Hemophilia A | - | - |
Vedolizumab SC | Phase 3 | Ulcerative Colitis | - | - |
Lubiprostone | Phase 3 | Constipation | - | - |
Metformin HCl | Phase 3 | Diabetes Mellitus | - | - |
TAK-667 | Phase 3 | Hereditary Angioedema | - | - |
Leuprorelin SR | Phase 3 | Prostatic Neoplasms, Locally Advanced | - | - |
VONVENDI | Phase 3 | Von Willebrand Disease (VWD) | - | - |
Gefarnate | Phase 3 | Stomach Ulcer | - | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
Intranasal Fentanyl Spray (INFS) | Phase 3 | Break Through Pain | - | - |
TVP-1012 0.5mg | Phase 3 | Parkinson's Disease | - | - |
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) | Phase 3 | Dengue Fever | - | - |
Metformin hydrochloride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Azilsartan | Phase 3 | Hypertension | - | - |
Lansoprazole microgranules suspension | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Peginesatide | Phase 3 | Anemia | - | - |
Concomitant Antibiotic Therapy | Phase 3 | Pouchitis | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. | Phase 3 | Hypertension | - | - |
TAK-743 300 mg | Phase 3 | Hereditary Angioedema | - | - |
Alogliptin and metformin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Cyclobenzaprine HCl | Phase 3 | Neck Pain | - | - |
TAK-625 | Phase 3 | Alagille Syndrome (ALGS) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Parathyroid Hormone (PTH) | Phase 3 | Osteoporosis | - | - |
TAK-003 | Phase 3 | Dengue Fever | - | - |
TAK-816 | Phase 3 | Healthy Volunteers | - | - |
Brigatinib | Phase 3 | ALK-positive Advanced NSCLC | - | - |
Lapaquistat Acetate | Phase 3 | Dyslipidemia | - | - |
Cyproterone acetate | Phase 3 | Adenocarcinoma, Prostate | - | - |
Escitalopram | Phase 3 | Treatment Outcome | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
TAK-816+ DPT-TAKEDA | Phase 3 | Immunization | - | - |
Lapaquistat acetate and lipid-lowering therapy | Phase 3 | Type 2 Diabetes | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Alectinib | Phase 3 | ALK+ Advanced NSCLC | - | - |
HAV Vaccine | Phase 3 | Healthy Volunteers | - | - |
Ramelteon | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
TDV | Phase 3 | Dengue Fever | - | - |
Dexlansoprazole MR | Phase 3 | Gastroesophageal Reflux Disease | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
SYR-472 | Phase 3 | Diabetes Mellitus | - | - |
TAK-583 | Phase 3 | Neuralgia, Postherpetic | - | - |
Darvadstrocel | Phase 3 | Crohn's Disease | - | - |
Omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-536CCB | Phase 3 | Grade I or II Essential Hypertension | - | - |
Lansoprazole and naproxen and aspirin | Phase 3 | Osteoarthritis | - | - |
Glyburide | Phase 3 | Diabetes Mellitus | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 3 | Colorectal Cancer | - | - |
Lapaquistat acetate and additional lipid-lowering therapy | Phase 3 | Hypercholesterolemia | - | - |
Vedolizumab | Phase 3 | Colitis, Ulcerative | - | - |
Pioglitazone and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Idursulfase-IT | Phase 3 | Hunter Syndrome | - | - |
Lanadelumab | Phase 3 | Angioedema | - | - |
Rapid-acting insulin secretagogue | Phase 3 | Diabetes Mellitus | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Candesartan | Phase 3 | Heart Failure | - | - |
Venticute | Phase 3 | Pneumonia | - | - |
Vortioxetine tablets | Phase 3 | Major Depressive Disorder | - | - |
Alogliptin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Azilsartan medoxomil - chlorthalidone | Phase 3 | Essential Hypertension | - | - |
Leuprorelin | Phase 3 | Prostatic Neoplasms | - | - |
Resatorvid | Phase 3 | Sepsis | - | - |
Vedolizumab 300 mg IV | Phase 3 | Colitis, Ulcerative | - | - |
Vedolizumab SC 108 mg | Phase 3 | Crohn's Disease | - | - |
Azilsartan medoxomil | Phase 3 | Essential Hypertension | - | - |
Alogliptin and glyburide | Phase 3 | Diabetes Mellitus | - | - |
Zasocitinib | Phase 3 | Psoriatic Arthritis | - | - |
SYR-322-MET | Phase 3 | Clinical Pharmacology | - | - |
TAK-438 10 mg | Phase 3 | Non-erosive Gastroesophageal Reflux Disease | - | - |
Vonicog Alfa | Phase 3 | Von Willebrand Disease (VWD) | - | - |
TAK-019 | Phase 3 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | - | - |
TAK-438 | Phase 3 | Gastric Ulcers | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension | - | - |
TAK-559 | Phase 3 | Diabetes Mellitus | - | - |
TAK-411 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) | Phase 2 | Dengue Fever | - | - |
Leuprorelin acetate | Phase 2 | Endometriosis | - | - |
Zasocitinib (Dose A) | Phase 2 | Hidradenitis Suppurativa | - | - |
Norwalk VLP vaccine | Phase 2 | Acute Gastroenteritis | - | - |
NoV Vaccine | Phase 2 | Healthy Volunteers | - | - |
TAK-981 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
TAK-954 | Phase 2 | Postoperative Gastrointestinal Dysfunction | - | - |
TAK-079 | Phase 2 | Primary Immune Thrombocytopenia | - | - |
TAK-063 20 mg | Phase 2 | Schizophrenia | - | - |
MCC-135 | Phase 2 | Congestive Heart Failure | - | - |
Brentuximab Vedotin | Phase 2 | Lymphoma | - | - |
Panitumumab + TAS-102 | Phase 2 | Colorectal Cancer | - | - |
Pevonedistat | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
TAK-071 | Phase 2 | Parkinson Disease | - | - |
Leuprorelin (GF) | Phase 2 | Uterine Fibroids | - | - |
Olmesartan | Phase 2 | Hypertension | - | - |
Candesartan cilexetil | Phase 2 | Essential Hypertension | - | - |
Lapaquistat acetate and fenofibrate | Phase 2 | Hyperlipidemias | - | - |
Hepatitis A Vaccine | Phase 2 | Healthy Volunteers | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
TAK-007 | Phase 2 | Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | - | - |
Ponatinib | Phase 2 | Myeloid Leukemia, Chronic, Chronic Phase | - | - |
TAK-853 | Phase 2 | Ovarian Cancer | - | - |
TAK-850 0.5 mL injection | Phase 2 | Influenza Infection | - | - |
TIMP-GLIA | Phase 2 | Celiac Disease | - | - |
TAK-662 | Phase 2 | Congenital Protein C Deficiency | - | - |
TAK-850 | Phase 2 | Influenza Infection | - | - |
GDX012 | Phase 2 | Leukemia | - | - |
TAK-188 | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Levothyroxine sodium new formulation | Phase 2 | Hypothyroidism | - | - |
TD-8954 | Phase 2 | Enteral Feeding Intolerance | - | - |
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) | Phase 2 | Dengue Fever | - | - |
TAK-341 | Phase 2 | Multiple System Atrophy | - | - |
Norovirus Bivalent VLP Vaccine | Phase 2 | Norovirus Prevention | - | - |
TAK-442 | Phase 2 | Acute Coronary Syndrome | - | - |
vortioxetine (Lu AA21004) | Phase 2 | Depressive Disorder, Major | - | - |
NDI-034858 | Phase 2 | Psoriatic Arthritis | - | - |
TAK-062 | Phase 2 | Celiac Disease | - | - |
Pioglitazone and insulin | Phase 2 | Diabetes Mellitus | - | - |
Ramelteon and doxepin | Phase 2 | Sleep Initiation and Maintenance Disorders | - | - |
Norovirus GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - | - |
Subcutaneous injection of TAK-850 | Phase 2 | Influenza Infection | - | - |
TAK-861 2 mg | Phase 2 | Narcolepsy Type 2 | - | - |
TAK-128 | Phase 2 | Diabetic Neuropathies | - | - |
TAK-385 | Phase 2 | Uterine Fibroids | - | - |
TAK-101 | Phase 2 | Celiac Disease | - | - |
Dazostinag | Phase 2 | Solid Neoplasms | - | - |
TAK-919 | Phase 2 | Coronavirus Disease (COVID-19) | - | - |
TAK-783 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Norovirus Bivalent Vaccine | Phase 2 | Prevention From Norovirus Infection | - | - |
Ilaprazole | Phase 2 | Esophagitis | - | - |
TDV Liquid Formulation 1 | Phase 2 | Dengue Fever | - | - |
Pioglitazone and atorvastatin | Phase 2 | Cardiovascular Diseases | - | - |
TAK-272 | Phase 2 | Type 2 Diabetes Mellitus and Microalbuminuria | - | - |
GI.1/GII.4 (15/15) | Phase 2 | Norovirus | - | - |
TAK-951 | Phase 2 | Postoperative Nausea and Vomiting (PONV) | - | - |
NDI-034858 study drug | Phase 2 | Moderate to Severe Plaque Psoriasis | - | - |
Namilumab | Phase 2 | Rheumatoid Arthritis | - | - |
TAK-788 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Pioglitazone and ramipril | Phase 2 | Inflammation | - | - |
TAK-935 | Phase 2 | Developmental and/or Epileptic Encephalopathies | - | - |
TAK-715 and methotrexate | Phase 2 | Arthritis, Rheumatoid | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
Pioglitazone and azilsartan | Phase 2 | Diabetes Mellitus | - | - |
psoriasis
3 drugs in this indication
narcolepsy
1 drug in this indication
sleep disorder
1 drug in this indication
Advanced colorectal cancer
1 drug in this indication
Narcolepsy Type 1
1 drug in this indication
Adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes
1 drug in this indication
polycythemia vera
1 drug in this indication
Fabry Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 201 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TAK) pipeline across Phase 3, Phase 2. Its lead program is Chlorthalidone (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TAK) next tracked catalyst is a Earnings expected October 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TAK biotech catalysts?→
Add TAK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.